# Clinical trial results:
# OPEN-LABEL, RANDOMIZED, THREE-ARM, PHASE IIIB CLINICAL STUDY TO INVESTIGATE THE SAFETY AND IMMUNOGENICITY OF A CONCOMITANT ADMINISTRATION OF GROUP C MENINGOCOCCAL POLYSACCHARIDE-TETANUS TOXOID CONJUGATE (MENC-TT) VACCINE AND 7-VALENT PNEUMOCOCCAL CRM197-CONJUGATE VACCINE (PCV7) IN TODDLERS PREVIOUSLY IMMUNIZED DURING INFANCY WITH PCV7

## Summary

| | |
|---|---|
| EudraCT number | 2007-004276-39 |
| Trial protocol | DE |
| Global end of trial date | 30 July 2009 |

**Results information**

| | |
|---|---|
| Result version number | v1 (current) |
| This version publication date | 29 June 2016 |
| First version publication date | 05 August 2015 |

## Trial information

**Trial identification**

| | |
|---|---|
| Sponsor protocol code | 670701 |

**Additional study identifiers**

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT00617760 |
| WHO universal trial number (UTN) | - |
| Other trial identifiers | Alias: B9361010 |

Notes:

**Sponsors**

| | |
|---|---|
| Sponsor organisation name | Pfizer Inc. |
| Sponsor organisation address | 235 E 42nd Street, New York, United States, NY 10017 |
| Public contact | Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com |
| Scientific contact | Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com |

Notes:

**Paediatric regulatory details**

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 29 March 2010 |
| Is this the analysis of the primary completion data? | No |

| | |
|---|---|
| Global end of trial reached? | Yes |
| Global end of trial date | 30 July 2009 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

To demonstrate that the concomitant administration of a single dose of MenC-TT vaccine and a PCV7 booster dose does not influence the immune response to any of the seven pneumococcal strains contained in PCV7 as compared to administration of PCV7 alone.

To demonstrate that the concomitant administration of a single dose MenC-TT vaccine and a PCV7 booster dose does not influence the immune response to the MenC-TT vaccine as compared to administration of MenC-TT vaccine alone.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial participants were followed.

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 25 March 2008 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Germany: 329 |
| Worldwide total number of subjects | 329 |
| EEA total number of subjects | 329 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 329 |

| | |
|---|---|
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 0 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

The study was conducted at 27 centers in Germany from 25 March 2008 to 30 July 2009. 333 subjects were enrolled in the study out of which 329 subjects were randomized. One subject randomized to the PCV7 group actually received both MenC-TT and PCV7. Subject disposition has been presented as per the actual treatment received.

### Period 1

| | |
|---|---|
| Period 1 title | Overall study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | MenC-TT + PCV7 |

Arm description:

Subjects recieved MenC-TT as primary immunization dose in combination with PCV7 as booster dose on Day 0 (vaccination visit).

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | MenC-TT |
| Investigational medicinal product code | |
| Other name | NeisVac-C |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received single 0.5 milliliter (mL) MenC-TT dose for primary immunization.

| | |
|---|---|
| Investigational medicinal product name | PCV7 |
| Investigational medicinal product code | |
| Other name | Prevenar |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received single 0.5 milliliter (mL) PCV7 dose for primary immunization.

| | |
|---|---|
| **Arm title** | PCV7 |

Arm description:

Subjects recieved intramuscularly 0.5 mL dose of Prevenar as a booster dose.

| | |
|---|---|
| Arm type | Active comparator |
| Investigational medicinal product name | PCV7 |
| Investigational medicinal product code | |
| Other name | Prevenar |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

A single 0.5 mL dose of Prevenar was administered as a booster dose on Day 0 (vaccination visit).

| | |
|---|---|
| **Arm title** | MenC-TT |

Arm description:

Subjects recieved intramuscularly 0.5mL of MenC-TT dose for primary immunization.

| | |
|---|---|
| Arm type | Active comparator |
| Investigational medicinal product name | MenC-TT |
| Investigational medicinal product code | |
| Other name | NeisVac-C |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

A single dose of 0.5mL of MenC-TT intramuscularly for primary immunization on Day 0 (vaccination visit).

| **Number of subjects in period 1** | MenC-TT + PCV7 | PCV7 | MenC-TT |
|---|---|---|---|
| Started | 166 | 81 | 82 |
| Completed | 165 | 78 | 82 |
| Not completed | 1 | 3 | 0 |
| Consent withdrawn by subject | - | 1 | - |
| Protocol violation | 1 | 2 | - |

## Baseline characteristics

| Reporting groups | |
|---|---|
| Reporting group title | MenC-TT + PCV7 |
| Reporting group description: | |
| Subjects recieved MenC-TT as primary immunization dose in combination with PCV7 as booster dose on Day 0 (vaccination visit). | |
| Reporting group title | PCV7 |
| Reporting group description: | |
| Subjects recieved intramuscularly 0.5 mL dose of Prevenar as a booster dose. | |
| Reporting group title | MenC-TT |
| Reporting group description: | |
| Subjects recieved intramuscularly 0.5mL of MenC-TT dose for primary immunization. | |

| Reporting group values | MenC-TT + PCV7 | PCV7 | MenC-TT |
|---|---|---|---|
| Number of subjects | 166 | 81 | 82 |
| Age categorical<br>Units: Subjects | | | |
| Age continuous<br>Units: months | | | |
| arithmetic mean | 13.4 | 13.3 | 13.6 |
| standard deviation | ± 1.48 | ± 1.55 | ± 1.59 |
| Gender categorical<br>Units: Subjects | | | |
| Female | 88 | 33 | 34 |
| Male | 78 | 48 | 48 |

| Reporting group values | Total | | |
|---|---|---|---|
| Number of subjects | 329 | | |
| Age categorical<br>Units: Subjects | | | |
| Age continuous<br>Units: months | | | |
| arithmetic mean | | | |
| standard deviation | - | | |
| Gender categorical<br>Units: Subjects | | | |
| Female | 155 | | |
| Male | 174 | | |

## End points

### End points reporting groups

| Reporting group title | MenC-TT + PCV7 |
|---|---|
| Reporting group description: | |
| Subjects recieved MenC-TT as primary immunization dose in combination with PCV7 as booster dose on Day 0 (vaccination visit). | |
| Reporting group title | PCV7 |
| Reporting group description: | |
| Subjects recieved intramuscularly 0.5 mL dose of Prevenar as a booster dose. | |
| Reporting group title | MenC-TT |
| Reporting group description: | |
| Subjects recieved intramuscularly 0.5mL of MenC-TT dose for primary immunization. | |

### Primary: Percentage of Subjects With PCV7-Specific Antibody Concentrations of Greater than or Equal to (>=) 0.2 Microgram/Milliliter (mcg/mL)

| End point title | Percentage of Subjects With PCV7-Specific Antibody Concentrations of Greater than or Equal to (>=) 0.2 Microgram/Milliliter (mcg/mL)[1] |
|---|---|

End point description:

Number of subjects achieving seroprotective PCV7-specific antibody concentrations for each of the 7 vaccine serotypes (14, 18C, 19F, 23F, 4, 6B, 9V) 1 month after the PCV booster vaccination were reported. Immunoglobulin G (IgG) antibody concentrations in response to the administration of PCV7 were determined by Enzyme linked immune sorbant assay (ELISA) with antibody concentrations >= 0.2 mcg/mL considered the serological correlate of protection. The per protocol (PP) analysis data set included all randomized and vaccinated subjects who fulfilled all inclusion and exclusion criteria, had no major protocol deviation, and had data available for the respective analysis.

| End point type | Primary |
|---|---|

End point timeframe:

1 month after vaccination

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint was planned to be assessed for only those reporting arms in which subjects received booster vaccination with PCV7.

| End point values | MenC-TT + PCV7 | PCV7 | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 159 | 77 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | | | | |
| Serotype 14 | 100 (97.5 to 100) | 100 (95.2 to 100) | | |
| Serotype 18C | 100 (97.6 to 100) | 100 (95.2 to 100) | | |
| Serotype 19F | 100 (97.5 to 100) | 98.7 (93 to 99.8) | | |
| Serotype 23F | 100 (97.5 to 100) | 100 (95.2 to 100) | | |
| Serotype 4 | 100 (97.6 to 100) | 100 (95.2 to 100) | | |
| Serotype 6B | 100 (97.5 to 100) | 98.7 (93 to 99.8) | | |

| | | | | |
|---|---|---|---|---|
| Serotype 9V | 100 (97.6 to 100) | 100 (95.2 to 100) | | |

## Statistical analyses

| **Statistical analysis title** | Statisctical Analysis of PVC7 >= 0.2 mcg/mL: 14 |
|---|---|
| Statistical analysis description: | |
| Non inferiority criteria margin is -10 percent (%). 95% Confidence Interval (CI) for the difference on the proportion of subjects with PVC7-Specific Antibody Concentration of >= 0.2 mcg/mL was calculated between MenC-TT + PCV7 vs PCV7. | |
| Comparison groups | MenC-TT + PCV7 v PCV7 |
| Number of subjects included in analysis | 236 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Difference in proportion |
| Point estimate | 0 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.8 |
| upper limit | 2.5 |

| **Statistical analysis title** | Statisctical Analysis of PVC7 >= 0.2 mcg/mL: 18C |
|---|---|
| Statistical analysis description: | |
| Non inferiority criteria margin is -10%. 95% CI for the difference on the proportion of subjects with PVC7-Specific Antibody Concentration of >= 0.2 mcg/mL was calculated between MenC-TT + PCV7 vs PCV7. | |
| Comparison groups | PCV7 v MenC-TT + PCV7 |
| Number of subjects included in analysis | 236 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Difference in proportion |
| Point estimate | 0 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.8 |
| upper limit | 2.4 |

| **Statistical analysis title** | Statisctical Analysis of PVC7 >= 0.2 mcg/mL: 19F |
|---|---|
| Statistical analysis description: | |
| Non inferiority criteria margin is -10%. 95% CI for the difference on the proportion of subjects with PVC7-Specific Antibody Concentration of >= 0.2 mcg/mL was calculated between MenC-TT + PCV7 vs PCV7. | |
| Comparison groups | MenC-TT + PCV7 v PCV7 |

| | |
|---|---|
| Number of subjects included in analysis | 236 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Difference in proportion |
| Point estimate | -1.3 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -7 |
| upper limit | 1.4 |

| **Statistical analysis title** | Statisctical Analysis of PVC7 >= 0.2 mcg/mL: 23F |
|---|---|

Statistical analysis description:

Non inferiority criteria margin is -10%. 95% CI for the difference on the proportion of subjects with PVC7-Specific Antibody Concentration of >= 0.2 mcg/mL was calculated between MenC-TT + PCV7 vs PCV7.

| | |
|---|---|
| Comparison groups | MenC-TT + PCV7 v PCV7 |
| Number of subjects included in analysis | 236 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Difference in proportion |
| Point estimate | 0 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.8 |
| upper limit | 2.5 |

| **Statistical analysis title** | Statistical analysis PCV7 >= 0.2 mcg/mL: 4 |
|---|---|

Statistical analysis description:

Non inferiority criteria margin is -10%. 95% CI for the difference on the proportion of subjects with PVC7-Specific Antibody Concentration of >= 0.2 mcg/mL was calculated between MenC-TT + PCV7 vs PCV7.

| | |
|---|---|
| Comparison groups | PCV7 v MenC-TT + PCV7 |
| Number of subjects included in analysis | 236 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Difference in proportion |
| Point estimate | 0 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.8 |
| upper limit | 2.4 |

| **Statistical analysis title** | Statistical analysis PCV7 >= 0.2 mcg/mL: 6B |
|---|---|
| Statistical analysis description: | |
| Non inferiority criteria margin is -10%. 95% CI for the difference on the proportion of subjects with PVC7-Specific Antibody Concentration of >= 0.2 mcg/mL was calculated between MenC-TT + PCV7 vs PCV7. | |
| Comparison groups | MenC-TT + PCV7 v PCV7 |
| Number of subjects included in analysis | 236 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Difference in proportion |
| Point estimate | -1.3 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -7 |
| upper limit | 1.4 |

| **Statistical analysis title** | Statistical analysis PCV7 >= 0.2 mcg/mL: 9V |
|---|---|
| Statistical analysis description: | |
| Non inferiority criteria margin is -10%. 95% CI for the difference on the proportion of subjects with PVC7-Specific Antibody Concentration of >= 0.2 mcg/mL was calculated between MenC-TT + PCV7 vs PCV7. | |
| Comparison groups | MenC-TT + PCV7 v PCV7 |
| Number of subjects included in analysis | 236 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Difference in proportion |
| Point estimate | 0 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.8 |
| upper limit | 2.4 |

## Primary: Percentage of Subjects With Seroprotective Meningococcal Serogroup C (MenC)-Specific Serum Bactericidal Activity (SBA) Titers >= 1:8

| End point title | Percentage of Subjects With Seroprotective Meningococcal Serogroup C (MenC)-Specific Serum Bactericidal Activity (SBA) Titers >= 1:8[2] |
|---|---|
| End point description: | |
| Number of subjects achieving seroprotective MenC-specific SBA titers 1 month after administration of MenC-TT vaccine were reported. Protection against serogroup C meningococcal disease correlated with the presence of anticapsular antibodies with SBA. A SBA titer of ≥ 1:8 was considered the serological correlate of protection for MenC vaccines. PP analysis data set contained all randomized and vaccinated subjects who fulfilled all inclusion and exclusion criteria, had no major protocol deviation, and had data available for the respective analysis. | |
| End point type | Primary |
| End point timeframe: | |
| 1 month after vaccination | |

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint was planned to be assessed for only those reporting arms in which subjects received vaccination with MenC-TT.

| **End point values** | MenC-TT + PCV7 | MenC-TT | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 159 | 80 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | 100 (97.6 to 100) | 100 (95.4 to 100) | | |

## Statistical analyses

| **Statistical analysis title** | Statistical analysis MenC-specific SBA titers ≥1:8 |
|---|---|

Statistical analysis description:

Non inferiority criteria margin is -10%. 95% CI for the difference on the proportion of subjects with MenC-specific SBA titers ≥1:8 was calculated between MenC-TT + PCV7 vs MenC-TT.

| | |
|---|---|
| Comparison groups | MenC-TT + PCV7 v MenC-TT |
| Number of subjects included in analysis | 239 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Difference in proportion |
| Point estimate | 0 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.6 |
| upper limit | 2.4 |

## Secondary: Number of Subjects With PCV7-Specific Antibody Concentrations >= 0.35 mcg/mL

| End point title | Number of Subjects With PCV7-Specific Antibody Concentrations >= 0.35 mcg/mL[3] |
|---|---|

End point description:

Number of subjects achieving PCV7-specific antibody concentrations for each of the 7 vaccine serotypes (14, 18C, 19F, 23F, 4, 6B, 9V) 1 month after the PCV booster vaccination was determined by ELISA. The intent to treat (ITT) data set contained all randomized and vaccinated subjects with available data for the respective analysis.

| End point type | Secondary |
|---|---|

End point timeframe:

1 month after vaccination

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint was planned to be assessed for only those reporting arms in which subjects received booster vaccination with PVC7.

| End point values | MenC-TT + PCV7 | PCV7 | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 164 | 80 | | |
| Units: Subjects | | | | |
| number (not applicable) | | | | |
| Serotype 14 | 156 | 80 | | |
| Serotype 18C | 158 | 80 | | |
| Serotype 19F | 155 | 79 | | |
| Serotype 23F | 154 | 80 | | |
| Serotype 4 | 158 | 80 | | |
| Serotype 6B | 155 | 79 | | |
| Serotype 9V | 158 | 80 | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With PCV7-Specific Antibody Concentrations >= 1 mcg/mL

| End point title | Number of Subjects With PCV7-Specific Antibody Concentrations >= 1 mcg/mL[4] |
|---|---|

End point description:

Number of subjects achieving PCV7-specific antibody concentrations for each of the 7 vaccine serotypes (14, 18C, 19F, 23F, 4, 6B, 9V) 1 month after the PCV booster vaccination was determined by ELISA. ITT data set contains all randomized and vaccinated subjects with available data for the respective analysis.

| End point type | Secondary |
|---|---|

End point timeframe:

1 month after vaccination

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint was planned to be assessed for only those reporting arms in which subjects received booster vaccination with PVC7.

| End point values | MenC-TT + PCV7 | PCV7 | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 164 | 80 | | |
| Units: Subjects | | | | |
| number (not applicable) | | | | |
| Serotype 14 | 156 | 80 | | |
| Serotype 18C | 145 | 73 | | |
| Serotype 19F | 153 | 76 | | |
| Serotype 23F | 150 | 77 | | |
| Serotype 4 | 153 | 80 | | |
| Serotype 6B | 151 | 79 | | |
| Serotype 9V | 152 | 80 | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Geometric Mean Concentration (GMC) for PCV7-Specific Antibody 1 Month After Booster Vaccination With PVC7

| End point title | Geometric Mean Concentration (GMC) for PCV7-Specific Antibody 1 Month After Booster Vaccination With PVC7[5] |
|---|---|

End point description:

PCV7-specific antibody GMC's 1 month after the PCV7 booster were assumed to be log-normally distributed. Concentration values were log-transformed, and their means and 95% Confidence Intervals (CIs) were calculated based on the t-distribution. ITT data set contains all randomized and vaccinated subjects with available data for the respective analysis.

| End point type | Secondary |
|---|---|

End point timeframe:

1 month after vaccination

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint was planned to be assessed for only those reporting arms in which subjects received booster vaccination with PVC7.

| End point values | MenC-TT + PCV7 | PCV7 | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 164 | 80 | | |
| Units: microgram per millilitre | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Serotype 14 | 10.94 (9.5 to 12.6) | 11.47 (9.41 to 13.99) | | |
| Serotype 18C | 3.82 (3.3 to 4.41) | 3.6 (2.91 to 4.45) | | |
| Serotype 19F | 7.14 (6.15 to 8.29) | 5.98 (4.65 to 7.69) | | |
| Serotype 23F | 6.1 (5.15 to 7.23) | 6.14 (4.89 to 7.7) | | |
| Serotype 4 | 5.34 (4.56 to 6.24) | 5.97 (4.85 to 7.36) | | |
| Serotype 6B | 11.05 (9.35 to 13.06) | 11.69 (9.05 to 15.09) | | |
| Serotype 9V | 3.78 (3.34 to 4.28) | 4.25 (3.6 to 5.01) | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Geometric Mean Titer (GMT) for MenC-Specific SBA 1 Month After Primary Vaccination with MenC-TT

| End point title | Geometric Mean Titer (GMT) for MenC-Specific SBA 1 Month After Primary Vaccination with MenC-TT[6] |
|---|---|

End point description:

MenC-specific SBA GMTs 1 month after vaccination with MenC-TT were assumed to be log-normally distributed. The ITT data set contains all randomized and vaccinated subjects with available data for the respective analysis.

| End point type | Secondary |
|---|---|

End point timeframe:

1 month after vaccination

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint was planned to be assessed for only those reporting arms in which subjects received vaccination with MenC-TT.

| **End point values** | MenC-TT + PCV7 | MenC-TT | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 164 | 81 | | |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | 1114.32 (946.63 to 1311.72) | 1429.68 (1162.12 to 1758.86) | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Seroconversion 1 Month After Vaccination With MenC-TT

| End point title | Number of Subjects With Seroconversion 1 Month After Vaccination With MenC-TT[7] |
|---|---|

End point description:

Seroconversion is a 4-fold increase in MenC-specific SBA titers, one month after vaccination. ITT data set contains all randomized and vaccinated subjects with available data for the respective analysis.

| End point type | Secondary |
|---|---|

End point timeframe:

1 month after vaccination

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint was planned to be assessed for only those reporting arms in which subjects received vaccination with MenC-TT.

| **End point values** | MenC-TT + PCV7 | MenC-TT | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 164 | 81 | | |
| Units: Subjects | | | | |
| number (not applicable) | 164 | 81 | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Geometric Mean Fold Increase in PCV7-Specific Antibody Concentrations From Before PCV7 Booster Vaccination to 1 Month After the PCV7 Booster

## Vaccination

| End point title | Geometric Mean Fold Increase in PCV7-Specific Antibody Concentrations From Before PCV7 Booster Vaccination to 1 Month After the PCV7 Booster Vaccination[8] |
|---|---|

End point description:

PCV7-specific antibody concentrations one month after booster vaccination with PCV7 were assumed to be log-normally distributed. Concentration values were log-transformed, and changes from baseline were calculated for each subject. Mean changes (95% CIs) from baseline were calculated based on the t-distribution. ITT data set contains all randomized and vaccinated subjects with available data for the respective analysis.

| End point type | Secondary |
|---|---|

End point timeframe:

Before PCV7 vaccination, 1 month after PCV7 vaccination

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The endpoint was planned to be assessed for only those reporting arms in which subjects received booster vaccination with PVC7.

| End point values | MenC-TT + PCV7 | PCV7 | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 164 | 80 | | |
| Units: Fold rise | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Serotype 14 | 4.62 (3.95 to 5.42) | 4.69 (3.78 to 5.83) | | |
| Serotype 18C | 9.56 (8.36 to 10.93) | 8.51 (7.12 to 10.17) | | |
| Serotype 19F | 10.08 (8.42 to 12.07) | 9.02 (7.03 to 11.58) | | |
| Serotype 23F | 10.26 (8.81 to 11.96) | 9.41 (7.63 to 11.61) | | |
| Serotype 4 | 9.77 (8.36 to 11.41) | 9.88 (7.88 to 12.39) | | |
| Serotype 6B | 9.16 (7.87 to 10.67) | 8.4 (6.53 to 10.8) | | |
| Serotype 9V | 5.86 (5.21 to 6.6) | 5.82 (4.89 to 6.93) | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Geometric Mean Fold Increase in MenC-specific SBA Titers From Before MenC-TT Primary Immunizaton Vaccination to 1 Month After Primary Immunization With MenC-TT

| End point title | Geometric Mean Fold Increase in MenC-specific SBA Titers From Before MenC-TT Primary Immunizaton Vaccination to 1 Month After Primary Immunization With MenC-TT[9] |
|---|---|

End point description:

MenC-specific SBA titers one month after vaccination with MenC-TT were assumed to be log-normally distributed. Titer values were log-transformed, and changes from baseline were calculated for each subject. Mean changes (95% CIs) from baseline were calculated based on the t-distribution. ITT data set contains all randomized and vaccinated subjects with available data for the respective analysis.

| End point type | Secondary |
|---|---|

End point timeframe:

Before MenC-TT vaccination, 1 month after MenC-TT vaccination

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint was planned to be assessed for only those reporting arms in which subjects received vaccination with MenC-TT.

| **End point values** | MenC-TT + PCV7 | MenC-TT | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 164 | 81 | | |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | 547.82 (464.7 to 645.81) | 690.79 (557.74 to 855.58) | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects Reporting Pre-Specified Injection Site Reactions

| End point title | Number of Subjects Reporting Pre-Specified Injection Site Reactions |
|---|---|

End point description:

The severity of injection site reactions was rated for Redness, induration, or swelling (diameter) as Mild (1.0–2.5 cm), Moderate (2.5.–5.0 cm) Severe (> 5.0 cm) and for Injection site pain or tenderness as Mild (No impairment of arm movement), Moderate (Impairment of arm movement) and Severe (Severe impairment, arm not moving). The safety analysis data set contains all vaccinated subjects. Unkown refers to injection site reactions whose severity score was missing because of a lesion size of less than 1 cm, i.e., less than mild.

| End point type | Secondary |
|---|---|

End point timeframe:

Within 1 month after vaccination

| **End point values** | MenC-TT + PCV7 | PCV7 | MenC-TT | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 166 | 81 | 82 | |
| Units: Subjects | | | | |
| number (not applicable) | | | | |
| Mild | 30 | 12 | 10 | |
| Moderate | 18 | 12 | 3 | |
| Severe | 2 | 5 | 1 | |
| Unknown | 32 | 8 | 10 | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects Reporting Pre-Specified Systemic Reactions

| End point title | Number of Subjects Reporting Pre-Specified Systemic Reactions |
|---|---|

End point description:

Systemic reactions are treatment-related systemic adverse events. Systemic reactions were reported in subject diary and includes vomiting, sweating, inconsolable or persisting crying, irritability, sleepiness, and food rejection. Unkown refers to injection site reactions whose severity score was missing because of a lesion size of less than 1 cm, i.e., less than mild.The safety analysis set contained all subjects vaccinated at least once with NeisVac-C.

| End point type | Secondary |
|---|---|

End point timeframe:

Within 1 month after vaccination

| End point values | MenC-TT + PCV7 | PCV7 | MenC-TT | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 166 | 81 | 82 | |
| Units: Subjects | | | | |
| number (not applicable) | | | | |
| Mild | 51 | 28 | 17 | |
| Moderate | 14 | 8 | 8 | |
| Severe | 1 | 0 | 0 | |
| Unknown | 0 | 0 | 0 | |
| Total with Reaction | 66 | 36 | 25 | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Local and Systemic Non-Serious Reactions Related to the Vaccination

| End point title | Number of Subjects With Local and Systemic Non-Serious Reactions Related to the Vaccination |
|---|---|

End point description:

Local reactions include induration, injection site pain, swelling, redness, and tenderness. Systemic reactions includes vomiting, sweating, inconsolable and persisting crying, irritability, sleepiness, and food rejection. The safety analysis data set contains all vaccinated subjects.

| End point type | Secondary |
|---|---|

End point timeframe:

Within 1 month after vaccination

| End point values | MenC-TT + PCV7 | PCV7 | MenC-TT | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 166 | 81 | 82 | |
| Units: Subjects | | | | |
| number (not applicable) | | | | |
| Food rejection | 4 | 2 | 5 | |
| Inconsolable/persisting crying | 1 | 7 | 11 | |
| Induration | 14 | 22 | 50 | |
| Injection site pain | 2 | 9 | 19 | |
| Irritability | 2 | 13 | 14 | |
| Redness | 11 | 27 | 67 | |
| Sleepiness | 7 | 13 | 16 | |
| Sweating | 1 | 2 | 4 | |
| Swelling | 3 | 16 | 27 | |
| Tenderness | 12 | 18 | 40 | |
| Vomiting | 1 | 1 | 1 | |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Within 1 month after vaccination

Adverse event reporting additional description:

SAEs and AEs were grouped by system organ class and summarized. AEs included AEs collected in subject diary (local and pre specified systemic reactions) and AEs collected on case report form at each visit. MedDRA dictionary version was not captured, here 0.0 is included for the MedDRA version.

| | |
|---|---|
| Assessment type | Non-systematic |

### Dictionary used

| | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 0.0 |

### Reporting groups

| | |
|---|---|
| Reporting group title | MenC-TT and PCV7 |

Reporting group description:

Subjects recieved MenC-TT as primary immunization dose in combination with PCV7 as booster dose on Day 0 (vaccination visit).

| | |
|---|---|
| Reporting group title | PCV7 |

Reporting group description:

Subjects recieved intramuscularly 0.5 mL dose of Prevenar as a booster dose.

| | |
|---|---|
| Reporting group title | MenC-TT |

Reporting group description:

Subjects recieved intramuscularly 0.5mL of MenC-TT dose for primary immunization.

| Serious adverse events | MenC-TT and PCV7 | PCV7 | MenC-TT |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 1 / 82 (1.22%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Nervous system disorders | | | |
| Febrile convulsion | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 0 / 81 (0.00%) | 1 / 82 (1.22%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Multiple | Additional description: "Multiple" includes subjects with more than one event reported under a single Reported Term". | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

Frequency threshold for reporting non-serious adverse events: 0 %

| **Non-serious adverse events** | MenC-TT and PCV7 | PCV7 | MenC-TT |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 105 / 166 (63.25%) | 56 / 81 (69.14%) | 34 / 82 (41.46%) |
| Injury, poisoning and procedural complications | | | |
| Contusion | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Fall | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Joint injury | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 1 / 82 (1.22%) |
| occurrences (all) | 1 | 0 | 1 |
| Mouth injury | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Poisoning | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vascular disorders | | | |
| Peripheral coldness | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nervous system disorders | | | |
| Crying | | | |
| subjects affected / exposed | 15 / 166 (9.04%) | 8 / 81 (9.88%) | 2 / 82 (2.44%) |
| occurrences (all) | 15 | 8 | 2 |
| Poor quality sleep | | | |
| subjects affected / exposed | 5 / 166 (3.01%) | 2 / 81 (2.47%) | 1 / 82 (1.22%) |
| occurrences (all) | 6 | 2 | 1 |
| Somnolence | | | |
| subjects affected / exposed | 19 / 166 (11.45%) | 15 / 81 (18.52%) | 7 / 82 (8.54%) |
| occurrences (all) | 19 | 15 | 7 |
| General disorders and administration site conditions | | | |

| | | | |
|---|---|---|---|
| Injection site pain | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 0 / 81 (0.00%) | 1 / 82 (1.22%) |
| occurrences (all) | 0 | 0 | 1 |
| Irritability | | | |
| subjects affected / exposed | 18 / 166 (10.84%) | 14 / 81 (17.28%) | 2 / 82 (2.44%) |
| occurrences (all) | 18 | 14 | 2 |
| Pyrexia | | | |
| subjects affected / exposed | 50 / 166 (30.12%) | 32 / 81 (39.51%) | 15 / 82 (18.29%) |
| occurrences (all) | 56 | 37 | 19 |
| Injection site erythema | | | |
| subjects affected / exposed | 67 / 166 (40.36%) | 27 / 81 (33.33%) | 11 / 82 (13.41%) |
| occurrences (all) | 86 | 27 | 11 |
| Injection site haematoma | | | |
| subjects affected / exposed | 3 / 166 (1.81%) | 0 / 81 (0.00%) | 1 / 82 (1.22%) |
| occurrences (all) | 3 | 0 | 1 |
| Injection site haemorrhage | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Injection site induration | | | |
| subjects affected / exposed | 50 / 166 (30.12%) | 22 / 81 (27.16%) | 14 / 82 (17.07%) |
| occurrences (all) | 69 | 22 | 14 |
| Injection site pain (Local reaction) | | | |
| subjects affected / exposed | 46 / 166 (27.71%) | 19 / 81 (23.46%) | 12 / 82 (14.63%) |
| occurrences (all) | 86 | 27 | 14 |
| Injection site swelling | | | |
| subjects affected / exposed | 27 / 166 (16.27%) | 16 / 81 (19.75%) | 3 / 82 (3.66%) |
| occurrences (all) | 32 | 16 | 3 |
| Multiple | Additional description: "Multiple" includes subjects with more than one event reported under a single Reported Term". | | |
| subjects affected / exposed | 6 / 166 (3.61%) | 6 / 81 (7.41%) | 2 / 82 (2.44%) |
| occurrences (all) | 8 | 7 | 2 |
| Ear and labyrinth disorders | | | |
| Ear pain | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Eye disorders | | | |

| | | | |
|---|---|---|---|
| Conjunctivitis | | | |
| subjects affected / exposed | 5 / 166 (3.01%) | 2 / 81 (2.47%) | 1 / 82 (1.22%) |
| occurrences (all) | 5 | 2 | 1 |
| Gastrointestinal disorders | | | |
| Aphthous stomatitis | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 1 / 82 (1.22%) |
| occurrences (all) | 1 | 0 | 1 |
| Constipation | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 0 / 81 (0.00%) | 1 / 82 (1.22%) |
| occurrences (all) | 0 | 0 | 1 |
| Diarrhoea | | | |
| subjects affected / exposed | 8 / 166 (4.82%) | 6 / 81 (7.41%) | 2 / 82 (2.44%) |
| occurrences (all) | 8 | 6 | 2 |
| Enteritis | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Faecal incontinence | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Faeces hard | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Teething | | | |
| subjects affected / exposed | 6 / 166 (3.61%) | 1 / 81 (1.23%) | 3 / 82 (3.66%) |
| occurrences (all) | 9 | 1 | 3 |
| Vomiting | | | |
| subjects affected / exposed | 5 / 166 (3.01%) | 4 / 81 (4.94%) | 4 / 82 (4.88%) |
| occurrences (all) | 5 | 5 | 4 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 6 / 166 (3.61%) | 2 / 81 (2.47%) | 2 / 82 (2.44%) |
| occurrences (all) | 6 | 2 | 2 |
| Skin and subcutaneous tissue disorders | | | |

| | | | |
|---|---|---|---|
| Dermatitis | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 0 / 81 (0.00%) | 1 / 82 (1.22%) |
| occurrences (all) | 0 | 0 | 1 |
| Dermatitis diaper | | | |
| subjects affected / exposed | 5 / 166 (3.01%) | 2 / 81 (2.47%) | 1 / 82 (1.22%) |
| occurrences (all) | 6 | 2 | 1 |
| Eczema | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 1 / 81 (1.23%) | 1 / 82 (1.22%) |
| occurrences (all) | 0 | 1 | 1 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 4 / 166 (2.41%) | 3 / 81 (3.70%) | 1 / 82 (1.22%) |
| occurrences (all) | 4 | 3 | 1 |
| Neurodermatitis | | | |
| subjects affected / exposed | 2 / 166 (1.20%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Petechiae | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rash | | | |
| subjects affected / exposed | 3 / 166 (1.81%) | 1 / 81 (1.23%) | 2 / 82 (2.44%) |
| occurrences (all) | 3 | 1 | 3 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 0 / 81 (0.00%) | 1 / 82 (1.22%) |
| occurrences (all) | 0 | 0 | 1 |
| Depressed mood | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Food aversion | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 10 / 166 (6.02%) | 2 / 81 (2.47%) | 4 / 82 (4.88%) |
| occurrences (all) | 10 | 2 | 4 |
| Insomnia | | | |
| subjects affected / exposed | 2 / 166 (1.20%) | 2 / 81 (2.47%) | 2 / 82 (2.44%) |
| occurrences (all) | 2 | 2 | 2 |
| Nervousness | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Restlessness | | | |
| subjects affected / exposed | 4 / 166 (2.41%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 4 | 1 | 0 |
| Sleep disorder | | | |
| subjects affected / exposed | 2 / 166 (1.20%) | 0 / 81 (0.00%) | 1 / 82 (1.22%) |
| occurrences (all) | 2 | 0 | 1 |
| Infections and infestations | | | |
| Abscess | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Acute tonsillitis | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Bacterial infection | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Bronchitis | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 2 / 81 (2.47%) | 1 / 82 (1.22%) |
| occurrences (all) | 1 | 2 | 1 |
| Bronchopneumonia | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Candida nappy rash | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eczema infected | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|---|---|---|---|
| Erythema infectiosum | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Exanthema subitum | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Febrile infection | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 1 / 82 (1.22%) |
| occurrences (all) | 1 | 0 | 1 |
| Fungal skin infection | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 1 / 82 (1.22%) |
| occurrences (all) | 1 | 0 | 1 |
| Gastroenteritis | | | |
| subjects affected / exposed | 4 / 166 (2.41%) | 1 / 81 (1.23%) | 3 / 82 (3.66%) |
| occurrences (all) | 4 | 1 | 3 |
| Gastroenteritis rotavirus | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gastrointestinal infection | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Genital candidiasis | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Influenza | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 7 / 166 (4.22%) | 3 / 81 (3.70%) | 3 / 82 (3.66%) |
| occurrences (all) | 7 | 3 | 3 |
| Otitis media | | | |
| subjects affected / exposed | 5 / 166 (3.01%) | 2 / 81 (2.47%) | 3 / 82 (3.66%) |
| occurrences (all) | 5 | 2 | 3 |

| | | | |
|---|---|---|---|
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Respiratory tract infection | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 11 / 166 (6.63%) | 5 / 81 (6.17%) | 1 / 82 (1.22%) |
| occurrences (all) | 11 | 5 | 1 |
| Sinobronchitis | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Tonsillitis | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 4 / 166 (2.41%) | 5 / 81 (6.17%) | 2 / 82 (2.44%) |
| occurrences (all) | 4 | 5 | 2 |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Varicella | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 0 / 81 (0.00%) | 1 / 82 (1.22%) |
| occurrences (all) | 0 | 0 | 1 |
| Viral infection | | | |
| subjects affected / exposed | 4 / 166 (2.41%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 4 | 1 | 0 |
| Viral rash | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|---|---|---|---|
| Viral upper respiratory tract infection | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Appetite disorder | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Decreased appetite | | | |
| subjects affected / exposed | 0 / 166 (0.00%) | 1 / 81 (1.23%) | 0 / 82 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Fluid imbalance | | | |
| subjects affected / exposed | 1 / 166 (0.60%) | 0 / 81 (0.00%) | 0 / 82 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 09 January 2008 | The protocol was amended to restrict the withdrawal of blood following 3 unsuccessful attempts in order to limit the stress caused on the subject. |

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported